AUS
NZ
UK
CA
USA
IND
Highlights
- European Approval for Illuccix®: Telix Pharmaceuticals received a positive decision on its Marketing Authorization Application (MAA) for Illuccix® across 18 European Economic Area (EEA) member states.
- Breakthrough in Prostate Cancer Imaging: Illuccix® leverages PSMA-PET imaging technology, which outperforms conventional imaging methods like CT and bone scans in prostate cancer staging and recurrence evaluation.
- Global Reach: Illuccix® has already been approved by regulatory authorities in the U.S., Australia, and Canada, solidifying its position as a key diagnostic tool for prostate cancer.
Telix Pharmaceuticals Limited (ASX:TLX, Nasdaq:TLX) announced a major regulatory milestone today with the approval of its prostate cancer imaging agent Illuccix® in Europe. The positive decision, reached via a decentralized procedure (DCP), paves the way for commercialization in 18 European Economic Area (EEA) member states.
This significant approval follows the issuance of the Final Assessment Report by Germany’s Federal Institute for Drugs and Medical Devices (BfArM), acting as the Reference Member State (RMS). The report was unanimously supported by all Concerned Member States (CMS), confirming that Illuccix® meets regulatory standards for marketing authorization. The process now transitions into the administrative national phase to implement the authorizations in each country, setting the stage for commercial launches.
A Game-Changer in Prostate Cancer Care
Illuccix® (gallium-68 gozetotide injection) utilizes PSMA-PET imaging technology, which has become the gold standard for diagnosing and managing prostate cancer. The imaging modality is recognized in clinical guidelines from leading organizations such as the European Association of Urology (EAU) and the European Society for Medical Oncology (ESMO).
PSMA-PET imaging offers unparalleled accuracy compared to traditional methods like CT or bone scans, particularly in staging primary prostate cancer and evaluating biochemical recurrence (BCR). Its ability to identify disease with precision makes it a transformative tool in prostate cancer management, addressing unmet needs in early and recurrent disease detection.
Global Regulatory Success
Illuccix® is Telix’s lead imaging product and has already received approvals from the U.S. Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA), and Health Canada. Its global adoption underscores the product’s clinical value and the growing need for innovative diagnostic solutions in prostate cancer care.
TLX shares jumped nearly 3% to AU$26.57 apiece at the time of writing on 17 January 2025.
